CLINICAL_TRIALS
trial_result
· 2017-10-16
Clinical Trial Update: Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) [Phase 4]
Summary
A Phase 4 clinical trial update reports results for a thermostable epoprostenol sodium formulation intended to treat pulmonary arterial hypertension.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 4 | Status: COMPLETED | Results posted: 2017-10-16